# A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

> **NCT07234162** · PHASE3 · RECRUITING · sponsor: **Dizal Pharmaceuticals** · enrollment: 218 (estimated)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Golidocitinib
- **DRUG:** Chidamide
- **DRUG:** Pralatrexate
- **DRUG:** Gemcitabine
- **DRUG:** Belinostat

## Key facts

- **NCT ID:** NCT07234162
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-13
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-10-31
- **Target enrollment:** 218 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07234162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07234162, "A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07234162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*